Please login to the form below

Not currently logged in
Email:
Password:

Belgium's TiGenix appoints Dr Gregory Gordon

He takes up a role as head of its US medical development

Gregory GordonBelgium biopharma firm TiGenix has appointed Dr Gregory Gordon to head up its US medical department as part of moves to strengthen its stateside operations.

TiGenix has also appointed Annette Valles-Sukkar as associate director, clinical projects, and both she and Dr Gordon will report to the company’s chief medical officer Dr Marie Paule Richard.

Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel.

Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

Dr Marie Paule Richard said: “We are delighted to welcome Gregory and Annette to TiGenix and to further build the team at our US headquarters in Cambridge, MA.

“Gregory has exceptional experience in drug development generally and specifically with gastrointestinal products. Annette has proven ability to manage large-scale late-stage clinical trials.”

3rd October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics